Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans.

MLA

Fangmann, Daniela, et al. “Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans.” Diabetes Care, vol. 41, no. 3, Mar. 2018, pp. 398–405. EBSCOhost, https://doi.org/10.2337/dc17-1967.

APA

Fangmann, D., Theismann, E.-M., Türk, K., Schulte, D. M., Relling, I., Hartmann, K., Keppler, J. K., Knipp, J.-R., Rehman, A., Heinsen, F.-A., Franke, A., Lenk, L., Freitag-Wolf, S., Appel, E., Gorb, S., Brenner, C., Seegert, D., Waetzig, G. H., Rosenstiel, P., & Schreiber, S. (2018). Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans. Diabetes Care, 41(3), 398–405. https://doi.org/10.2337/dc17-1967

Chicago

Fangmann, Daniela, Eva-Maria Theismann, Kathrin Türk, Dominik M. Schulte, Isabelle Relling, Katharina Hartmann, Julia K. Keppler, et al. 2018. “Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans.” Diabetes Care 41 (3): 398–405. doi:10.2337/dc17-1967.